Indivior logo

INDV - Indivior News Story

165p 6.5  4.1%

Last Trade - 30/07/21

Market Cap £1.16bn
Enterprise Value £689.8m
Revenue £482.8m
Position in Universe 407th / 1800

UPDATE 1-Indivior looks beyond opioid addiction with foray into cannabis disorder treatment

Tue 8th June, 2021 2:10pm
(Adds CEO comment, background)
    June 8 (Reuters) - Indivior  INDV.L  said on Tuesday it was
expanding into medicines for cannabis-related disorders, as the
British drugmaker looks to diversify beyond core sales of
opioid-addiction treatments.
    London-listed Indivior said it has agreed to pay $30 million
upfront to Aelis Farma, a privately held French company, under
an agreement to work exclusively on its lead experimental drug,
which blocks a type of cannabinoid receptor. (
    Cannabinoids are naturally occurring compounds found in the
cannabis plant and they include THC, the psychoactive component
which causes hallucinations.
    Aelis Farma's drug, AEF0117, inhibits the CB1 receptor found
largely in the nervous system and also some other tissues. The
receptor helps in communicating sensations such as pain, and
regulating memory and eating behaviour.
    The treatment, which Aelis has worked on for seven years,
selectively inhibits the CB1 receptor when the body has been
made hyperactive and preserves other routine body functions, the
French company said. (
    The treatment had shown positive results in an early-to-mid
stage trial with patients who had cannabis addiction. Aelis is
eligible for $100 million more, if the next trial stage is
successful, as well as income from milestone payments and sales,
Indivior said.
    "Increasing prevalence of cannabis from the growing movement
to legalize medical and recreational marijuana use is leading to
greater concern for the potential of adverse outcomes, including
elevated addiction risk," Indivior Chief Executive Officer Mark
Crossley said.
    An estimated 192 million people worldwide used cannabis in
2018, making it the most used drug in the world, the United
Nations said in a report last year. (

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak
 ((; Twitter: @pullthekart; Mobile:
+91 852 751 3793))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.